0
Supernus Pharmaceuticals, Inc. Banner Image

Supernus Pharmaceuticals, Inc. has reached its limit for free report views

Work for Supernus Pharmaceuticals, Inc.? Upgrade Your Profile and unlock all your annual reports.

Supernus Pharmaceuticals, Inc.

  • Ticker SUPN
    Exchange NASDAQ More
  • Industry Drug Manufacturers - Other More
  • Sector Healthcare More
Supernus Pharmaceuticals, Inc. Logo Image
  • 201-500 Employees
  • Based in Rockville, Maryland
Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company currently markets Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, and Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy. TheMore Company is also developing several product candidates to address large market opportunities in the CNS market, including SPN-810 for the treatment of Impulsive Aggression in ADHD patients, SPN-812 for the treatment of ADHD and SPN-604 for the treatment of bipolar disorder.
Supernus Pharmaceuticals, Inc.

Most Recent Annual Report

Supernus Pharmaceuticals, Inc. MOST RECENT 2020 Annual Report and Form 10K

Report Locked. Supernus Pharmaceuticals, Inc. has reached its limit for free report views.

Older/Archived Annual Reports